27 May 2023
: Case report 
Vulvar Leiomyosarcomas: A Case Series with Clinical Comparison to Uterine Leiomyosarcomas and Review of the Literature
Mistake in diagnosis, Rare disease
Stephanie Verta
1ACDEF*, Zaher Alwafai 2BE, Nika Schleede2BE, Christine E. Brambs 1ACDE, Corina Christmann 1DE, Verena Reichert2B, Marek Zygmunt2ACDE, Birgit Plattner3BC, Günter Köhler2ABCDEF
DOI: 10.12659/AJCR.939402
Am J Case Rep 2023; 24:e939402
Table 1. Clinical data of vulvar and uterine leiomyosarcomas of the DKSM database.
| VLMS | ULMS | Significance (P value) | |
|---|---|---|---|
| n | 8 | 276 | – |
| Stage 1/2 | 50/50 | 85.9/14.1 | – |
| Age (years) median/mean, range | 59.8/54, 45–81 | 53.0/51, 25–80 | 0.08 |
| Postmenopause (%) | 37.5 | 53.6 | 0.48 |
| Rapid growth (%) | 100 | 75 | – |
| Misdiagnosis (%) | 66.7 (Bartholin’s gland abscess/cyst) | 75 (leiomyoma) | – |
| Tumor diameter (cm) | 4.9, 2.5–7.6 | 10.3, 1.5–40 | <0.01 |
| Lymphadenectomy (%) | 0 | 14 | – |
| External beam radiation (%) | 37.5 | 3.4 | – |
| Chemotherapy (%) | 0 | 8 | – |
| Follow-up (months) median, range | 73, 16–106 | 49, 2–220 | – |
| Overall survival (%) | 100 | 59 | 0.043 |
| VLMS – vulvar leiomyosarcoma; ULMS – uterine leiomyosarcoma. | |||